AbbVie Buying Capstan Therapeutics In $2.1 Billion Deal
By Amit Chowdhry ● Jun 30, 2025
AbbVie and Capstan Therapeutics (a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs) announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309 (a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase 1, in development for the treatment of B cell-mediated autoimmune diseases). Plus, AbbVie will buy Capstan's proprietary tLNP platform technology designed to deliver RNA payloads, such as mRNA, which is capable of engineering specific cell types in vivo.